Engineering and Improving Anti–CTLA-4 Checkpoint Inhibitors
Galvez-Cancino F., Parkes EE., Withers DR., Melero I.
Summary Next-generation anti–CTLA-4 antibodies have been designed and tested to improve the efficacy and therapeutic index by leveraging enhanced Fc-mediated effector function with conditional tumor-restricted activation. The goal is to achieve robust antitumor activity without inducing systemic immune-related toxicity. See related article by Jhatakia et al., p. XX .